For Doctors in a Hurry
- Clinicians lack clear guidance for managing peripheral edema in patients with advanced cancer, which significantly impairs their quality of life.
- The researchers conducted a scoping review of 31 studies involving 2,223 patients to characterize causes, treatments, and clinical outcomes.
- Reported interventions including stenting, diuretics, and physical therapy produced measurable short-term improvements in symptom burden across the analyzed cohorts.
- The authors conclude that peripheral edema stems from diverse, overlapping mechanisms requiring targeted, mechanism-based management strategies for effective symptom control.
- Physicians should prioritize standardized assessments to guide individualized care while awaiting more robust prospective data on these therapeutic interventions.
The Clinical Challenge of Edema in Advanced Malignancy
In the landscape of advanced oncology, clinicians frequently encounter systemic complications that severely compromise a patient's remaining quality of life. While much attention is focused on managing the toxicities of modern immunotherapies [1, 2, 3] or adhering to rigorous guidelines for primary tumor treatment [4], secondary symptomatic burdens often remain under-researched. Peripheral edema is one such complication, frequently arising as a side effect of systemic therapies like taxanes or targeted inhibitors [5, 6]. For instance, a phase II trial comparing albumin-bound docetaxel to standard docetaxel found that peripheral edema occurred in 16.1% of the experimental group versus 4.8% in the control arm [5]. A scoping review of 31 studies involving 2,223 patients now characterizes the diverse mechanisms driving this condition, such as malignant inferior vena cava obstruction (a blockage of the primary vein returning blood from the lower body to the heart), and evaluates the efficacy of targeted clinical interventions [7]. These findings suggest that mechanism-based strategies, including stenting or decongestive physical therapy, can yield meaningful improvements in symptom burden [7].
Mapping the Evidence for Palliative Edema Management
The researchers conducted a scoping review following a five-step methodology, utilizing a predefined protocol registered on the Open Science Framework to ensure transparency and reproducibility. To identify relevant literature, the team searched MEDLINE, Embase, and the Cochrane Library for studies published between 2010 and June 30, 2023. The inclusion criteria focused on adult patients experiencing peripheral edema specifically related to advanced cancer, its associated treatments, or concurrent comorbidities. This broad scope allowed for a comprehensive look at how edema manifests in the palliative setting, where multiple physiological factors often overlap. The selection process involved two independent reviewers who screened titles, abstracts, and full texts to extract data, ensuring a rigorous evaluation of the available evidence. From an initial pool of 426 publications, 31 studies met the inclusion criteria. This final selection comprised a diverse range of evidence levels, including 10 observational studies involving 2,128 patients, 5 case series with 79 patients, and 16 case reports involving 16 patients. By aggregating these data, the researchers aimed to characterize the diverse causes and management strategies used in clinical practice for this patient population, which often faces limited prognoses. To evaluate the reliability of the findings, the researchers assessed the quality of the observational studies using the Effective Public Health Practice Project’s tool (a standardized instrument used to evaluate the methodological rigor of clinical research by examining factors like selection bias and data collection methods). Among the 10 observational studies, the quality ratings were generally low, with 6 studies rated as moderate and 4 studies rated as weak. This distribution highlights a significant gap in high-quality, prospective evidence for managing edema in advanced malignancy, suggesting that while current mechanism-based interventions show utility, clinicians must often rely on data from studies with inherent methodological limitations.
Identifying Drivers Beyond Lymphatic Dysfunction
Peripheral edema is a common complication in advanced cancer that significantly impacts patients’ quality of life, often leading to decreased mobility, skin breakdown, and psychological distress. While clinicians frequently associate limb swelling in oncology with lymphedema, the findings of this scoping review clarify that the condition can result from various causes beyond lymphatic dysfunction. This clinical reality necessitates a mechanism-based management approach (a strategy where treatment is tailored to the specific underlying physiological driver of the symptom rather than applying a generic protocol for fluid retention). The researchers identified several specific drivers of fluid accumulation across the analyzed literature. Among the 10 observational studies involving 2,128 patients, the reported causes of edema included overhydration, malignant inferior vena cava obstruction (a blockage of the primary vein returning blood from the lower body to the heart due to tumor compression or invasion), and multiple risk factors occurring simultaneously. Because these mechanisms are often overlapping, a patient may present with edema driven by a combination of venous insufficiency, hypoalbuminemia, and the side effects of systemic therapies, requiring a diagnostic process that looks beyond simple lymphatic obstruction. Most studies included in the review involved patients with limited prognoses, a factor that underscores the urgency of effective symptom management. For individuals in the advanced stages of malignancy, the primary goal of treating peripheral edema is the rapid reduction of symptom burden to maintain comfort and function. The researchers concluded that by identifying whether the edema stems from fluid overload, venous compression, or other systemic factors, clinicians can implement targeted interventions that provide meaningful short-term relief for patients whose remaining time is limited.
Targeted Interventions and Clinical Outcomes
The management of peripheral edema in the context of advanced malignancy requires a shift from generalized fluid management to precise, mechanism-guided strategies. Within the scoping review, seven observational studies addressed specific treatment interventions, frequently utilizing multimodal approaches (the combination of different therapeutic modalities to address the multifactorial nature of the condition). These strategies were tailored to the underlying pathophysiology identified in each patient. For instance, in cases where edema was driven by mechanical venous compression, inferior vena cava stenting (the surgical placement of a mesh tube to reopen a collapsed or obstructed major vein) was employed. In other clinical scenarios, the researchers utilized parenteral fluid management (the careful adjustment of intravenous fluids to prevent or correct overhydration) and medication management including the use of diuretics to address systemic fluid overload. Beyond pharmacological and surgical interventions, the review highlighted the utility of decongestive physical therapy interventions, such as specialized massage and compression techniques, to facilitate fluid drainage. The data indicate that these mechanism-based interventions can yield meaningful short-term improvements in symptom burden, a critical outcome for patients with limited prognoses. Specifically, targeted management such as hydration or medication management, decongestive therapy, or inferior vena cava stenting produced measurable benefits in reducing limb volume and improving patient comfort. These findings underscore a significant clinical need for the development of standardized assessment tools to accurately categorize edema types at the bedside. Furthermore, the authors emphasize the necessity for more prospective studies (research that follows patients forward in time to observe outcomes) to strengthen the evidence base and refine individualized, mechanism-driven care for this vulnerable population.
References
1. Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. CA A Cancer Journal for Clinicians. 2020. doi:10.3322/caac.21596
2. Bertrand A, Kostine M, Barnetche T, Truchetet M, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine. 2015. doi:10.1186/s12916-015-0455-8
3. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology. 2021. doi:10.1200/jco.21.01440
4. Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2020. doi:10.6004/jnccn.2020.0016
5. Wang Z, Chen D, Li H, et al. Phase II randomized clinical trial comparing albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology. 2024. doi:10.1200/jco.2024.42.16_suppl.e16018
6. Khan I, Ahmed FS, Hanif N, et al. Role of capmatinib in MET exon 14-mutated advanced non-small cell lung cancer (NSCLC): A systematic review.. 2021. doi:10.1200/JCO.2021.39.15_SUPPL.E21150
7. Tennison JM, Sharma EG, Lee R, Dev R, Farris DP, Bruera E. Peripheral Edema in Advanced Cancer: Mechanisms and Management-A Scoping Review.. Journal of palliative medicine. 2026. doi:10.1177/10966218261440404
